Enovis Appoints Damien McDonald as CEO, Reaffirms Q1 Guidance

On April 2, 2025, Enovis Corporation announced the appointment of Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald will also join the Board of Directors following the Annual Meeting on May 21, 2025. He succeeds Matt Trerotola, who previously announced his retirement and will not seek re-election.

McDonald brings over 35 years of experience in the medical device industry, including his tenure as CEO of LivaNova and leadership roles at Danaher, Zimmer, and Johnson & Johnson. He is recognized for driving growth, profitability, and fostering a strong, patient-focused company culture.

The company also reaffirmed its Q1 2025 guidance, with expected revenues between $555 million and $563 million and adjusted EBITDA between $97 million and $100 million.

Lead Independent Director Sharon Wienbar praised McDonald’s leadership track record and announced she will assume the role of independent Chair following Trerotola’s departure. Enovis will address questions regarding the leadership transition during its earnings call on May 8, 2025.

Enovis is a medical technology growth company focused on innovative orthopedic and patient outcome-driven solutions. More information is available at [www.enovis.com](https://www.enovis.com).

Enovis Corporation reported strong financial results for the fourth quarter and full year 2024, with significant growth in sales and earnings. Fourth-quarter net sales reached $561 million, a 23% increase from the previous year, driven by strong performance in Global Reconstructive and steady execution in Prevention & Recovery. Reconstructive sales grew by 59% on a reported basis, with a 10% increase in comparable sales. The company also reported an adjusted EBITDA of $113 million, or 20% of sales, representing a 210-basis-point improvement over the prior year.

For the full year 2024, Enovis achieved net sales of $2.1 billion, marking a 23% increase from 2023. Reconstructive sales saw a 60% jump, while Prevention & Recovery grew by 2%. Adjusted EBITDA for the year was $377 million, up 210 basis points year over year. Despite these gains, the company posted a net loss from continuing operations of $827 million due to a $645 million goodwill impairment charge.

Enovis has set its financial outlook for 2025, expecting revenue between $2.19 billion and $2.22 billion, with organic revenue growth of 6-6.5%. Adjusted EBITDA is projected to be between $405 million and $415 million, with adjusted earnings per share expected to range from $3.10 to $3.25.

Additionally, the company announced a planned CEO transition, with Matt Trerotola set to retire once a successor is appointed. Enovis continues to focus on integrating recent acquisitions, launching new products, and driving sustainable growth. A conference call to discuss these results is scheduled, with further details available on the company's website.